does smoking lower clozapine and olanzapine levels by 30-50%?
“This induction can lower clasapine and olanzapine levels by as much as 30-50% compared to non-smokers.”
a host, a psychiatry resident said on PsychEd: Educational Psychiatry Podcast, 2026-09-01, at 06:51. hear it in context →
the episode: PsychEd Shorts 16: CYP Metabolism (at 06:51). we link the show's own page; we do not re-host audio.
first, the part that holds
the speaker is right: tobacco smoke induces cyp1a2, and the main pooled analysis puts the gap at about 30% for olanzapine and about 50% for clozapine. the 30-50% range matches that meta-analysis.
what we found when we went and looked
we read a 2014 meta-analysis in bmj open. it pooled 7 olanzapine studies (1,094 patients) and 4 clozapine studies (196 patients). in smokers, the concentration-to-dose ratio was lower for both drugs: by −0.75 (ng/ml)/(mg/day) for olanzapine and −1.11 for clozapine. the authors turned that into dose equivalents. a smoker on 10 mg of olanzapine matches a non-smoker on about 7 mg, which is about 30% lower. a smoker on 200 mg of clozapine matches a non-smoker on about 100 mg, which is about 50% lower. the fda clozapine label calls tobacco smoke "a moderate inducer of cyp1a2." the 30% belongs to olanzapine and the 50% to clozapine. these are pooled averages, and one later study of people made to stop smoking found a smaller change.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| tobacco smoke induces cyp1a2, the enzyme that breaks down clozapine and olanzapine | confirmed | the fda clozapine label says "tobacco smoke is a moderate inducer of cyp1a2" and says to consider a lower dose when an inducer is stopped. the olanzapine label lists nonsmoking status as a factor that can slow olanzapine metabolism. neither label gives a percentage for smoking in the sections we could read. [2][3] |
| smokers have clozapine levels up to about 50% lower than non-smokers | confirmed | pooled across 4 studies (196 patients), the concentration-to-dose ratio was lower in smokers by −1.11 (ng/ml)/(mg/day), 95% ci −1.53 to −0.70. the authors work out that a smoker on 200 mg matches a non-smoker on about 100 mg, about 50% lower. this rests on a small pooled sample with no adjustment for age, sex, weight or how much people smoked. [1] |
| smokers have olanzapine levels up to about 30% lower than non-smokers | confirmed | pooled across 7 studies (1,094 patients), the concentration-to-dose ratio was lower in smokers by −0.75 (ng/ml)/(mg/day), 95% ci −0.89 to −0.61, with little heterogeneity (i2 = 11%). the authors work out that a smoker on 10 mg matches a non-smoker on about 7 mg, about 30% lower. [1] |
| popular reading: both drugs drop by 30-50% in every smoker | overstated | the range is split by drug: about 30% for olanzapine, about 50% for clozapine. these are group averages, not a ceiling or a guarantee for any one person. in a 2023 study of 53 hospitalized men in china who had to stop smoking, dose-corrected clozapine levels rose 23.5%. that means levels while smoking were about 19% lower, smaller than the meta-analysis figure. the paper describes earlier reports as 20-40%. [1] |
both directions
for the speaker: the 2014 meta-analysis gives the speaker's numbers drug by drug: about 30% for olanzapine and about 50% for clozapine. the olanzapine result rests on 1,094 patients with little heterogeneity. the fda clozapine label names tobacco smoke as a cyp1a2 inducer and warns that levels can rise when an inducer is stopped. the olanzapine label treats nonsmoking status as a reason metabolism may be slower. a 2023 study of people forced to stop smoking found clozapine levels went up afterwards, which shows the induction effect directly.
against: "30-50%" is not one range for both drugs. 30% is the olanzapine estimate and 50% is the clozapine estimate. the clozapine estimate comes from only 4 studies and 196 patients. in the 2023 study of 53 men in china, dose-corrected clozapine rose only 23.5% after enforced smoking cessation, and the authors cite earlier work at 20-40% lower in smokers, below the 50% figure. "as much as" makes these sound like maximums, but they are averages, and some individual patients will differ by more or less.
what this cannot say
the meta-analysis compares different people (smokers against non-smokers), not the same people before and after. it did not adjust for age, sex, weight, how much people smoked, or other medicines, and it only included english-language papers indexed in medline, scopus and cochrane. the cessation study had a short window, men only, one hospital, and no non-smoking control group. we could not get the pharmacokinetics section of the olanzapine label to load, so we do not cite the clearance figure it may contain. several pubmed and pmc pages were blocked for us, so we could not read some primary studies that are often cited (including a 2006 norwegian study), and we have not used them.
sources, each one fetched and read
- Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open 2014;4(3):e004216 What we read there: olanzapine (7 studies, 1,094 patients): c/d ratio lower in smokers, mean difference −0.75 (ng/mL)/(mg/day) (95% CI −0.89 to −0.61); clozapine (4 studies, 196 patients): mean difference −1.11 (95% CI −1.53 to −0.70); doses should be reduced by 30% (olanzapine) and 50% (clozapine) in non-smokers compared with smokers, e.g. 200 mg of clozapine in smokers ≈ 100 mg in non-smokers. Fetched 2026-10-13 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC3948577
- US FDA-approved prescribing information, clozapine tablets (DailyMed setid 90876802-0e3a-44c9-9ff7-1754dfbe736a) What we read there: "Tobacco smoke is a moderate inducer of CYP1A2." Also: consider reducing the dosage when discontinuing coadministered enzyme inducers, "because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions." Fetched 2026-10-13 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90876802-0e3a-44c9-9ff7-1754dfbe736a
- US FDA-approved prescribing information, olanzapine tablets and orally disintegrating tablets (DailyMed setid b418946a-1ab4-4d89-a012-d94fc361a3c4) What we read there: a lower starting dose is advised for patients with factors that may slow olanzapine metabolism, "(e.g., nonsmoking female patients ≥65 years of age)"; "nonsmoking status" is listed among factors that may slow metabolism. Fetched 2026-10-13 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b418946a-1ab4-4d89-a012-d94fc361a3c4
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam